Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Liabilities and Shareholders Equity (2016 - 2025)

Alterity Therapeutics has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $13.9 million for Q2 2019.

  • For Q2 2019, Liabilities and Shareholders Equity fell 1.62% year-over-year to $13.9 million; the TTM value through Jun 2019 reached $10.2 billion, down 46.48%, while the annual FY2019 figure was $13.9 million, 1.62% down from the prior year.
  • Liabilities and Shareholders Equity for Q2 2019 was $13.9 million at Alterity Therapeutics, down from $10.1 billion in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $32.5 billion in Q2 2015 and troughed at $13.9 million in Q2 2019.
  • A 5-year average of $9.7 billion and a median of $27.8 million in 2015 define the central range for Liabilities and Shareholders Equity.
  • On a YoY basis, Liabilities and Shareholders Equity climbed as much as 60068.82% in 2018 and fell as far as 99.93% in 2018.
  • Year by year, Liabilities and Shareholders Equity stood at $27.8 million in 2015, then decreased by 17.86% to $22.8 million in 2016, then decreased by 26.07% to $16.9 million in 2017, then surged by 60068.82% to $10.1 billion in 2018, then tumbled by 99.86% to $13.9 million in 2019.
  • Business Quant data shows Liabilities and Shareholders Equity for ATHE at $13.9 million in Q2 2019, $10.1 billion in Q4 2018, and $14.2 million in Q2 2018.